This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morton, D. H.
Right arrow Articles by Kelley, R. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morton, D. H.
Right arrow Articles by Kelley, R. I.
Related Collections
Right arrow Office Practice

PEDIATRICS Vol. 109 No. 6 June 2002, pp. 999-1008

Diagnosis and Treatment of Maple Syrup Disease: A Study of 36 Patients

D. Holmes Morton, MD*, Kevin A. Strauss, MD*, Donna L. Robinson, CRNP*, Erik G. Puffenberger, PhD* and Richard I. Kelley, MD, PhD{ddagger}

* Clinic for Special Children, Strasburg Pennsylvania
{ddagger} Kennedy Krieger Institute and Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland

Objective. To evaluate an approach to the diagnosis and treatment of maple syrup disease (MSD).

Methods. Family histories and molecular testing for the Y393N mutation of the E1{alpha} subunit of the branched-chain {alpha}-ketoacid dehydrogenase allow us to identify infants who were at high risk for MSD. Amino acid concentrations were measured in blood specimens from these at-risk infants between 12 and 24 hours of age. An additional 18 infants with MSD were diagnosed between 4 and 16 days of age because of metabolic illness.

A treatment protocol for MSD was designed to 1) inhibit endogenous protein catabolism, 2) sustain protein synthesis, 3) prevent deficiencies of essential amino acids, and 4) maintain normal serum osmolarity. Our protocol emphasizes the enhancement of protein anabolism and dietary correction of imbalances in plasma amino acids rather than removal of leucine by dialysis or hemofiltration. During acute illnesses, the rate of decrease of the plasma leucine level was monitored as an index of net protein synthesis. The treatment protocol for acute illnesses included the use of mannitol, furosemide, and hypertonic saline to maintain or reestablish normal serum sodium and extracellular osmolarity and thereby prevent or reverse life-threatening cerebral edema. Similar principles were followed for both sick and well outpatient management, especially during the first year, when careful matching of branched-chain amino acid intake with rapidly changing growth rates was necessary. Branched-chain ketoacid excretion was monitored frequently at home and branched-chain amino acid levels were measured within the time of a routine clinic visit, allowing immediate diagnosis and treatment of metabolic derangements.

Results. 1) Eighteen neonates with MSD were identified in the high-risk group (n = 39) between 12 and 24 hours of age using amino acid analysis of plasma or whole blood collected on filter paper. The molar ratio of leucine to alanine in plasma ranged from 1.3 to 12.4, compared with a control range of 0.12 to 0.53. None of the infants identified before 3 days of age and managed by our treatment protocol became ill during the neonatal period, and 16 of the 18 were managed without hospitalization.

2) Using our treatment protocol, 18 additional infants who were biochemically intoxicated at the time of diagnosis recovered rapidly. In all infants, plasma leucine levels decreased to <400 µmol/L between 2 to 4 days after diagnosis. Rates of decrease of the plasma leucine level using a combination of enteral and parenteral nutrition were consistently higher than those reported for dialysis or hemoperfusion. Prevention of acute isoleucine, valine, and other plasma amino acid deficiencies by appropriate supplements allowed a sustained decrease of plasma leucine levels to the therapeutic range of 100 to 300 µmol/L, at which point dietary leucine was introduced.

3) Follow-up of the 36 infants over >219 patient years showed that, although common infections frequently cause loss of metabolic control, the overall rate of hospitalization after the neonatal period was only 0.56 days per patient per year of follow-up, and developmental outcomes were uniformly good. Four patients developed life-threatening cerebral edema as a consequence of metabolic intoxication induced by infection, but all recovered. These 4 patients each showed evidence that acutely decreased serum sodium concentration and decreased serum osmolarity were associated with rapid progression of cerebral edema during their acute illnesses.

Conclusions. Classical MSD can be managed to allow a benign neonatal course, normal growth and development, and low hospitalization rates. However, neurologic function may deteriorate rapidly at any age because of metabolic intoxication provoked by common infections and injuries. Effective management of the complex pathophysiology of this biochemical disorder requires integrated management of general medical care and nutrition, as well as control of several variables that influence endogenous protein anabolism and catabolism, plasma amino acid concentrations, and serum osmolarity.

Key Words: branched-chain ketoacid dehydrogenase • maple syrup disease • Mennonite • newborn screening • leucine • isoleucine valine • essential amino acid deficiencies • neutral amino acid transporter • blood brain barrier • dystonia • metabolic disease • Guthrie bacterial inhibition assay • tandem mass spectrometry

Abbreviations: MSD, Maple syrup disease • BCKD, branched-chain {alpha}-ketoacid dehydrogenase • BCAA, branched-chain amino acids • CSC, Clinic for Special Children • MRI, magnetic resonance imaging • L1-NAA-t, L1-neutral amino acid transporter.

Received for publication Jun 22, 1999; Accepted Jan 24, 2002.




This article has been cited by other articles:


Home page
 Clin. Chem.Home page
D. Oglesbee, K. A. Sanders, J. M. Lacey, M. J. Magera, B. Casetta, K. A. Strauss, S. Tortorelli, P. Rinaldo, and D. Matern
Second-Tier Test for Quantification of Alloisoleucine and Branched-Chain Amino Acids in Dried Blood Spots to Improve Newborn Screening for Maple Syrup Urine Disease (MSUD)
Clin. Chem., March 1, 2008; 54(3): 542 - 549.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
P.S. Bindu, K.E. Shehanaz, R. Christopher, P. K. Pal, and S. Ravishankar
Intermediate Maple Syrup Urine Disease: Neuroimaging Observations in 3 Patients From South India
J Child Neurol, July 1, 2007; 22(7): 911 - 913.
[Abstract] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
A. Hasenoehrl, T. Galic, G. Ergovic, N. Marsic, M. Skerlev, J. Mittendorf, U. Geschke, A. Schmidt, and W. Schoenfeld
In Vitro Activity and In Vivo Efficacy of Icofungipen (PLD-118), a Novel Oral Antifungal Agent, against the Pathogenic Yeast Candida albicans.
Antimicrob. Agents Chemother., September 1, 2006; 50(9): 3011 - 3018.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
S. Kolker, S. W. Sauer, J. G. Okun, G. F. Hoffmann, and D. M. Koeller
Lysine intake and neurotoxicity in glutaric aciduria type I: towards a rationale for therapy?
Brain, August 1, 2006; 129(Pt 8): e54 - e54.
[Full Text] [PDF]

Home page
 BrainHome page
W. J. Zinnanti, J. Lazovic, E. B. Wolpert, D. A. Antonetti, M. B. Smith, J. R. Connor, M. Woontner, S. I. Goodman, and K. C. Cheng
A diet-induced mouse model for glutaric aciduria type I
Brain, April 1, 2006; 129(4): 899 - 910.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
M. Yudkoff, Y. Daikhin, I. Nissim, O. Horyn, B. Luhovyy, A. Lazarow, and I. Nissim
Brain Amino Acid Requirements and Toxicity: The Example of Leucine
J. Nutr., June 1, 2005; 135(6): 1531S - 1538S.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
H. Mitsubuchi, M. Owada, and F. Endo
Markers Associated with Inborn Errors of Metabolism of Branched-Chain Amino Acids and Their Relevance to Upper Levels of Intake in Healthy People: An Implication from Clinical and Molecular Investigations on Maple Syrup Urine Disease
J. Nutr., June 1, 2005; 135(6): 1565S - 1570S.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
E. J. Schoen, J. C. Baker, C. J. Colby, and T. T. To
Cost-Benefit Analysis of Universal Tandem Mass Spectrometry for Newborn Screening
Pediatrics, October 1, 2002; 110(4): 781 - 786.
[Abstract] [Full Text] [PDF]